Palisade Bio rises on 'sufficient' trial data for bowel function drug

Palisade Bio

16/12/2022 14:02

** Shares of drug developer Palisade Bio  PALI.O  rise 4.8%
to $2.4 in premarket trade
    ** Co says it has collected sufficient data for evaluation
purposes, and is ceasing enrollment in mid-stage trial of its
post-surgery bowel function drug, LB1148  urn:newsml:reuters.com:*:nGNX6rZvV8
    ** Topline data readout from 35 patients in the study is
expected in H1 2023
    ** PALI says drug neutralizes digestive enzymes to
potentially reduce intestinal damage and accelerate return of
bowel function after abdominal surgery
    ** Co is currently designing a dose optimization study for
all indications to determine if a different dosing protocol
would enhance drug's risk profile
    ** Dose optimization study enrollment expected to start in
the first half of 2023 
    ** Up to last close, Palisade stock down 96.5% YTD
 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((nandhini.srinivasan@thomsonreuters.com))